Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

InMed Pharmaceuticals Inc. (C:IN)

Business Focus: Bio Therapeutic Drugs

Jun 30, 2020 06:18 pm ET
InMed Announces Completion of Share Consolidation
Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020...
Jun 30, 2020 06:18 pm ET
InMed Announces Completion of Share Consolidation
Trading of Consolidated Shares on TSX Expected to Begin on July 3rd, 2020
Jun 24, 2020 07:30 am ET
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
VANCOUVER, BC, June 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high q...
Jun 24, 2020 07:30 am ET
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
VANCOUVER, BC, June 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high quality
Jun 19, 2020 06:20 pm ET
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
VANCOUVER, BC, June 19, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission ("SEC") in connection with a proposed offering of up to US$12 million of common shares (the "Offering"). In connection with the proposed Offering, InMed has also applied
Jun 19, 2020 06:20 pm ET
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
VANCOUVER, BC, June 19, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN) (OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission ("SEC") in connection with a proposed offering of up to US$12 million of common shares (the "Offering"). In connection with the proposed Offering, InMed has also a...
May 27, 2020 07:30 am ET
InMed Releases CBN Preclinical Results in Glaucoma
VANCOUVER, May 27, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today provided an update on the preclinical results from its INM-088 drug development program that indicate a potential neuroprotective effect of cannabinol ("CBN") on nerve cells located in the eye. INM-088 is being developed as a potential treatment option for ocular diseases, such as glaucoma, wh...
May 27, 2020 07:30 am ET
InMed Releases CBN Preclinical Results in Glaucoma
VANCOUVER, May 27, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today provided an update on the preclinical results from its INM-088 drug development program that indicate a potential neuroprotective effect of cannabinol ("CBN") on nerve cells located in the eye. INM-088 is being developed as a potential treatment option for ocular diseases, such as glaucoma, where neu
May 19, 2020 07:30 am ET
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
VANCOUVER, May 19, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") patent application directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids....
May 19, 2020 07:30 am ET
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
VANCOUVER, May 19, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced the filing of a key Patent Cooperation Treaty ("PCT") patent application directed to the Company's biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids.
May 14, 2020 07:30 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, May 14, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year 2020 ("3Q20") which ended March 31, 2020....
May 14, 2020 07:30 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, May 14, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today reported financial results for the third quarter of fiscal year 2020 ("3Q20") which ended March 31, 2020.
May 12, 2020 07:30 am ET
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
VANCOUVER, May 12, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma....
May 12, 2020 07:30 am ET
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
VANCOUVER, May 12, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma.
May 08, 2020 07:30 am ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
VANCOUVER, May 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 ending March 31, 2020 (3Q20), on Thursday, May 14, 2020....
May 08, 2020 07:30 am ET
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
VANCOUVER, May 8, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year 2020 ending March 31, 2020 (3Q20), on Thursday, May 14, 2020.
May 07, 2020 07:30 am ET
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
VANCOUVER, May 7, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), announced that Eric. A. Adams, President & CEO of InMed, will present a corporate overview as part of the upcoming virtual conference:...
May 07, 2020 07:30 am ET
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
VANCOUVER, May 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), announced that Eric. A. Adams, President & CEO of InMed, will present a corporate overview as part of the upcoming virtual conference:
May 05, 2020 07:30 am ET
InMed and Almac Group Developing Improved Cannabinoid Production Methods
VANCOUVER, May 5, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it is working with the Almac Group (UK) ("Almac") on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production....
May 05, 2020 07:30 am ET
InMed and Almac Group Developing Improved Cannabinoid Production Methods
VANCOUVER, May 5, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that it is working with the Almac Group (UK) ("Almac") on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
Apr 30, 2020 07:30 am ET
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
VANCOUVER, April 30, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct its second Phase 1 trial with INM-755....
Apr 30, 2020 07:30 am ET
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
VANCOUVER, April 30, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct its second Phase 1 trial with INM-755.
Apr 01, 2020 07:30 am ET
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, April 1, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation.
Apr 01, 2020 07:30 am ET
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, April 1, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced that all subjects participating in its 755-101-HV Phase 1 clinical trial have completed treatment and clinical evaluation....
Mar 24, 2020 07:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
VANCOUVER, March 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers. ...
Mar 24, 2020 07:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
VANCOUVER, March 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers.
Mar 20, 2020 07:30 am ET
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
VANCOUVER, March 20, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations. ...
Mar 20, 2020 07:30 am ET
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
VANCOUVER, March 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today provided an update on the impact of the global outbreak of COVID-19 on its business operations.
Mar 10, 2020 01:24 pm ET
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
VANCOUVER, March 10, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Feb 20, 2020 09:15 am ET
Edison issues update on InMed Pharmaceuticals (IN)
LONDON, UK / ACCESSWIRE / February 20, 2020 / InMed Pharmaceuticals (TSX:IN) recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis bullosa (EB), is currently around 50% enrolled with full enrollment expected this quarter and data in H220. This trial is testing two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. The company expects to file a clinical trial application (CTA) for a second trial (755-102-HV) this quarter with initiation in Q220. This upcoming trial would test INM-
Feb 14, 2020 06:30 am ET
Feb 07, 2020 06:30 am ET
InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020
VANCOUVER, Feb. 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the second quarter of fiscal year 2020 ending December 31, 2019 ("2Q20"), on Friday, February 14, 2020.
Jan 21, 2020 06:30 am ET
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
VANCOUVER, Jan. 21, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today published additional information describing in detail its leading cannabinol-based therapeutics programs on its corporate website at www.inmedpharma.com.
Jan 20, 2020 06:30 am ET
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
VANCOUVER, Jan. 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting diseases with high unmet medical needs, today revealed the rare cannabinoid  cannabinol ("CBN") as the active pharmaceutical ingredient ("API") in its two product candidates under development: INM-755 for epidermolysis bullosa ("EB") and INM-088 for glaucoma. InMed is leading the way in the clinical development of CBN to treat human disease.
Jan 16, 2020 06:30 am ET
InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress
VANCOUVER, Jan. 16, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that members of its senior scientific and clinical team will be attending the EB2020 World Congress, organized and funded by the Dystrophic Epidermolysis Bullosa Research Association (DEBRA), from January 19-23, 2020 in London, UK.
Jan 10, 2020 04:56 pm ET
InMed Announces Election of Directors
VANCOUVER, Jan. 10, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today confirmed that at its annual general meeting of shareholders held on December 19, 2019 (the "Meeting"), all directors nominated as listed in the information circular dated November 7, 2019 were elected as directors of the Company for the ensuing year. InMed filed a report of voting results on SEDAR at www.sedar.com on December 20, 2019.
Jan 08, 2020 06:30 am ET
InMed Pharmaceuticals to Present at the Biotech Showcase Conference
VANCOUVER, Jan. 8, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President & CEO will be presenting at the Biotech Showcase conference to be held at the Hilton San Francisco Union Square in San Francisco, California from January 13-15, 2020.
Dec 09, 2019 06:30 am ET
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
VANCOUVER, Dec. 9, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application ("CTA") to conduct a Phase 1 trial in the Netherlands for INM-755, a cannabinoid-based topical cream.  The Company intends to initiate subject recruitment immediately. 
Nov 18, 2019 08:45 am ET
Edison issues update on InMed Pharmaceuticals
LONDON, UK / ACCESSWIRE / November 18, 2019 / InMed Pharmaceuticals (TSX:IN) recently announced that it filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for epidermolysis bullosa. Approval of the CTA is expected around the end of November with the first trial (755-101-HV) expected to begin in December. This trial will test two strengths of INM-755 cream on the intact skin of 22 healthy volunteers. Following the completion of this trial, the company expects to initiate trial 755-102-HV, which would test INM-755 on eight healthy volunte
Nov 11, 2019 07:30 am ET
InMed Pharmaceuticals to Present at the Cowen Conference
VANCOUVER, Nov. 11, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric Hsu, Senior Vice President, Preclinical Research and Development, will be participating at Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston.
Nov 11, 2019 07:30 am ET
InMed Pharmaceuticals to Present at the Cowen Conference
VANCOUVER, Nov. 11, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric Hsu, Senior Vice President, Preclinical Research and Development, will be participating at Cowen 2nd Annual Boston Cannabis Conference being held on November 12th and 13th, 2019, at the InterContinental Boston....
Nov 08, 2019 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, Nov. 8, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20").
Nov 08, 2019 06:30 am ET
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
VANCOUVER, Nov. 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20")....
Nov 05, 2019 06:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
VANCOUVER, Nov. 5, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. ...
Nov 05, 2019 06:30 am ET
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
VANCOUVER, Nov. 5, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.
Nov 04, 2019 06:30 am ET
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
VANCOUVER, Nov. 4, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20"), on Friday, November 8, 2019.
Nov 04, 2019 06:30 am ET
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
VANCOUVER, Nov. 4, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20"), on Friday, November 8, 2019....
Oct 18, 2019 12:25 pm ET
InMed Pharmaceuticals to Present at the BIO Investor Forum
VANCOUVER, Oct. 18, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco:
Oct 18, 2019 12:25 pm ET
InMed Pharmaceuticals to Present at the BIO Investor Forum
VANCOUVER, Oct. 18, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco:...
Sep 26, 2019 07:35 am ET
Edison Issues Update on InMed Pharmaceuticals (IN)
LONDON, UK / ACCESSWIRE / September 26, 2019 / InMed (IN) recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will consist of two trials, one in healthy volunteers with intact skin and the other in healthy volunteers with small wounds. A Phase I/II trial in EB patients is expected to begin in Q121. In glaucoma, the company has switched its lead candidate to INM-088, which has some specific advantages to the former lead, INM-085. Advanced preclinical and formulation developme
Sep 23, 2019 11:00 am ET
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
VANCOUVER, Sept. 23, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Karen Long, InMed's Senior Director, Drug Development, will be presenting at the Regulatory Affairs Professionals Society's annual conference at the Philadelphia Convention Center in Philadelphia, 21-24 September 2019....
Sep 23, 2019 11:00 am ET
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
VANCOUVER, Sept. 23, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that Karen Long, InMed's Senior Director, Drug Development, will be presenting at the Regulatory Affairs Professionals Society's annual conference at the Philadelphia Convention Center in Philadelphia, 21-24 September 2019.
Sep 03, 2019 07:25 am ET
Sep 03, 2019 07:25 am ET
Aug 29, 2019 07:25 am ET
InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
InMed's Eric Hsu and Michael Woudenberg among Event's Expert Speakers...
Aug 29, 2019 07:25 am ET
InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
InMed's Eric Hsu and Michael Woudenberg among Event's Expert Speakers
Jul 02, 2019 07:25 am ET
May 15, 2019 07:25 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
VANCOUVER, May 15, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 ("3Q19")....
May 15, 2019 07:25 am ET
InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
VANCOUVER, May 15, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2019, which is the Company's third quarter of fiscal year 2019 ("3Q19").
Mar 13, 2019 07:25 am ET
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success...
Mar 13, 2019 07:25 am ET
Feb 14, 2019 08:02 am ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed (IN) recently reported results for the second quarter of FY19 and is on track to bring INM-750 for epidermolysis bullosa (EB) into the clinic by the end of the year. The company recently completed two topical seven-day dose-ranging studies in...
Nov 21, 2018 04:26 am ET
Edison issues update on InMed Pharmaceuticals (IN)
InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration...
Nov 01, 2018 06:00 am ET
BTV Explores Tech Companies on Investors' Radar
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2018) - On BNN Sat Nov. 3 & Sun Nov. 4, 2018 - BTV- Business Television visits state-of-the-art technology companies ranging from social media to pharmaceuticals. Full Episode
Oct 10, 2018 07:25 am ET
Sep 25, 2018 07:25 am ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Compa...
Sep 25, 2018 07:25 am ET
InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
VANCOUVER, Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's in
Sep 13, 2018 07:25 am ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18").
Sep 13, 2018 07:25 am ET
InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
VANCOUVER, Sept. 13, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18")....
Sep 11, 2018 07:25 am ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthe
Sep 11, 2018 07:25 am ET
InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
VANCOUVER, Sept. 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the bi...
Sep 07, 2018 07:25 am ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018.
Sep 07, 2018 07:25 am ET
InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
VANCOUVER, Sept. 7, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018....
Aug 01, 2018 07:25 am ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston....
Aug 01, 2018 07:25 am ET
InMed to Present at the Canaccord Genuity 38th Annual Growth Conference
VANCOUVER, Aug. 1, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston.
Jun 21, 2018 11:13 am ET
InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Jun 12, 2018 09:54 am ET
InMed Pharmaceuticals announces increase in Bought Deal offering to $13 million
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase, as underwriter, 14,444,560...
Jun 12, 2018 07:30 am ET
InMed Pharmaceuticals Announces $10 Million Bought Deal
InMed Pharmaceuticals Inc. (TSX:IN) (“InMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, as underwriter, under which Eight Capital has agreed to purchase 11,111,200 units of the...
May 29, 2018 07:25 am ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California. 
May 29, 2018 07:25 am ET
InMed to Present at the 8th Annual LD Micro Invitational Conference
VANCOUVER, May 29, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the 8th annual LD Micro Invitational conference on June 4th, 2018, at 2:00 PM PST at the Luxe Sunset Bel Air in Los Angeles, California.  ...
May 14, 2018 07:25 am ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a pr...
May 14, 2018 07:25 am ET
InMed Files Patent Application for INM-085 Glaucoma Program
VANCOUVER, May 14, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced it has filed a Patent Cooperation Treaty ("PCT") application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority
May 11, 2018 07:25 am ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18")....
May 11, 2018 07:25 am ET
InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update
VANCOUVER, May 11, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").
May 04, 2018 08:30 am ET
OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX
NEW YORK, May 4, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced InMed Pharmaceuticals Inc. (TSX: IN; OTCQX: IMLFF), a cannabinoid-focused biopharmaceutical company, has qualified to trade on the OTCQX® Best Market.  InMed Pharmaceuticals upgraded to OTCQX from the OTCQB® Venture Market....
May 01, 2018 08:30 am ET
May 01, 2018 08:30 am ET
Apr 17, 2018 10:31 am ET
InMed Pharmaceuticals Inc. Opens the Market
TORONTO, April 17, 2018 /CNW/ - Eric Adams, President & CEO, InMed Pharmaceuticals Inc. (IN), joined Shaun McIver, Chief Client Officer, TMX Group, to open the market. InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed Pharmaceuticals Inc. commenced trading on Toronto Stock Exchange on March 26, 2018.
Apr 17, 2018 08:00 am ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018....
Apr 17, 2018 08:00 am ET
InMed Rings the Opening Bell at the Toronto Stock Exchange
VANCOUVER, April 17, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange ("TSX") today in honor of its migration to the exchange on March 26, 2018.
Apr 11, 2018 08:00 am ET
Mar 23, 2018 06:00 am ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018
Mar 23, 2018 06:00 am ET
InMed Pharmaceuticals Announces Graduation to Toronto Stock Exchange
Trading on the TSX will commence March 26, 2018...
Mar 12, 2018 07:30 am ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed'...
Mar 12, 2018 07:30 am ET
InMed to Present at 30th Annual ROTH Capital Conference
VANCOUVER, March 12, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed's prese
Mar 06, 2018 03:30 am ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model
Mar 06, 2018 03:30 am ET
InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research
Publication on a Novel Hydrogel Formulation for the Treatment of Glaucoma Helps Validate InMed's Fully Integrated, Cannabinoid-based Business Model ...
Mar 02, 2018 06:30 am ET
Jan 04, 2018 11:29 am ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 11:28 am ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 09:08 am ET
IIROC Trade Resumption - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - Trading resumes in:
Jan 04, 2018 09:04 am ET
IIROC Trading Halt - IN
VANCOUVER, Jan. 4, 2018 /CNW/ - The following issues have been halted by IIROC:
Jan 04, 2018 05:00 am ET
InMed Closes Over-Subscribed C$9.4 Million Financing
/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES/
Dec 22, 2017 08:30 am ET
CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis
New York, New York--(Newsfile Corp. - December 22, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 21, 2017 08:30 am ET
CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry
New York, New York--(Newsfile Corp. - December 21, 2017) - CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 20, 2017 10:17 am ET
IIROC Trade Resumption - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - Trading resumes in:
Dec 20, 2017 08:46 am ET
IIROC Trading Halt - IN
VANCOUVER, Dec. 20, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 18, 2017 04:15 pm ET
Dec 18, 2017 08:30 am ET
NetworkNewsWire Announces Publication on the Value of Cannabinoid-based Alternatives to Opioids
New York, New York--(Newsfile Corp. - December 18, 2017) - NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 18, 2017 07:00 am ET
Horizons ETFs Expands the Portfolio of its Marijuana-Focused ETF
Upon quarterly rebalance, 11 stocks were added to the HMMJ portfolio
Dec 14, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoid-Based Therapies
New York, New York--(Newsfile Corp. - December 14, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 14, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing the Potential of Cannabinoid-Based Pain Therapies
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and...
Dec 13, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential
NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and...
Dec 11, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Advances in Cannabinoids for use in Pain Management
New York, New York--(Newsfile Corp. - December 11, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 08, 2017 07:30 am ET
UPDATE - NetworkNewsWire Announces Publication featuring Advances in Cannabinoid Products and Therapies for Pain Management
NEW YORK, Dec. 08, 2017 (GLOBE NEWSWIRE) -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a preclinical stage biopharmaceutical company specializing in the research...
Dec 07, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Advances in the Manufacture of Cannabinoid Compounds for Medical Purposes
New York, New York--(Newsfile Corp. - December 7, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Dec 07, 2017 08:30 am ET
NetworkNewsWire Announces Publication on the Use of Cannabinoids for Pain Management and other Medical Applications  
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a preclinical stage biopharmaceutical company specializing in the research...
Nov 17, 2017 08:30 am ET
NetworkNewsWire Announces Publication on Innovative Research Being Developed on Cannabinoid-Based Therapies, Drugs
New York, New York--(Newsfile Corp. - November 17, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Nov 16, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Biotech Advances in Cannabis Research
New York, New York--(Newsfile Corp. - November 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
Nov 16, 2017 07:00 am ET
Nov 16, 2017 07:00 am ET
Nov 09, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing M&A Activity Driven by the Convergence of Cannabis and Medicine
New York, New York--(Newsfile Corp. - November 9, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Nov 06, 2017 09:00 am ET
CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. (CSE: IN)(CSE: IN.CN)(CNSX: IN)(OTCQB: IMLFF). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive
Nov 06, 2017 09:00 am ET
CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First
Seattle, Washington--(Newsfile Corp. - November 6, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive video interview with Eric A. Adams, CEO of InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (OTCQB: IMLFF). In this interview, CEO Eric A. Adams talks about the company's recent breakthrough, a study in which the team was able to identify a cannabinoid drug candidate for the treatment of glaucoma; biosynthesize that cannabinoid; develop a proprietary hydrogel delivery system; and effectively apply the new drug to the eye in a positive preclinical study.
Nov 02, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Innovative Extraction Methods Used in the Production of Cannabinoids
New York, New York--(Newsfile Corp. - November 2, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 30, 2017 08:30 am ET
NetworkNewsWire Announces Publication Discussing Unique R&D in the Medicinal Marijuana Industry
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 30, 2017 08:30 am ET
NetworkNewsWire Announces Publication Highlighting Advances in CBD Development
New York, New York--(Newsfile Corp. - October 30, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 26, 2017 08:30 am ET
NetworkNewsWire Announces Publication on Biosynthesis for Medicinal-Grade Cannabinoids
New York, New York--(Newsfile Corp. - October 26, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Oct 24, 2017 06:00 am ET
InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
VANCOUVER, Oct. 24, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav).
Oct 24, 2017 06:00 am ET
InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid
VANCOUVER, Oct. 24, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today results from a study co-sponsored by InMed (Dr. Sazzad Hossain, Chief Scientific Officer) and the University of British Columbia (laboratories of Profs. Ujendra Kumar and Vikramaditya Yadav). ...
Oct 17, 2017 07:00 am ET
InMed Updates Pain Program
CSE: INOTCQB: IMLFF
Oct 17, 2017 07:00 am ET
InMed Updates Pain Program
CSE: INOTCQB: IMLFF...
Oct 10, 2017 07:00 am ET
Oct 10, 2017 07:00 am ET
Oct 03, 2017 07:00 am ET
Oct 03, 2017 07:00 am ET
Oct 03, 2017 06:00 am ET
NetworkNewsWire Announces Publication that Highlights the Limitless Potential of Innovative Drug Development
New York, New York--(Newsfile Corp. - October 3, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.
Sep 21, 2017 06:00 am ET
InMed Pharmaceuticals Added to CSE25 Index
VANCOUVER, Sept. 21, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index. ...
Sep 21, 2017 06:00 am ET
InMed Pharmaceuticals Added to CSE25 Index
VANCOUVER, Sept. 21, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index.
Sep 20, 2017 08:30 am ET
InMed Pharma: A Leader in Cannabinoid Biosynthesis -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering how InMed Pharmaceuticals Inc. (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) is leveraging biosynthesis to solve a major problem in the medical cannabis industry as it adds key ex-Eli Lilly personnel to its efforts.
Sep 19, 2017 06:00 am ET
Sep 19, 2017 06:00 am ET
Sep 12, 2017 06:00 am ET
Sep 12, 2017 06:00 am ET
Sep 07, 2017 09:00 am ET
Biosynthesis Could Reduce Regulatory Hurdles for Cannabis Researchers -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article examining InMed Pharmaceuticals' (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) biosynthesis program and how it could address many vexing issues with cannabis drug development.
Aug 18, 2017 09:00 am ET
Jul 27, 2017 09:00 am ET
Jul 27, 2017 09:00 am ET
Jul 13, 2017 09:00 am ET
InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article covering InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CNSX: IN) new research and development deal with ATERA SAS of France and the company's development of INM-750 for the treatment of epidermolysis bullosa (EB).
Jul 10, 2017 08:00 am ET
InMed Signs R&D Agreement with ATERA
CSE: IN OTCQB: IMLFF...
Jul 10, 2017 08:00 am ET
Jun 14, 2017 09:00 am ET
InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media
CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing InMed Pharmaceuticals Inc. (CNSX: IN) (OTCQB: IMLFF) and the progress it is making in advancing its lead clinical trial candidate.
Jun 13, 2017 09:00 am ET
Jun 13, 2017 09:00 am ET
May 31, 2017 11:31 am ET
InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
May 24, 2017 02:16 pm ET
IIROC Trade Resumption - IN
VANCOUVER, May 24, 2017 /CNW/ - Trading resumes in: